The Chiaramello Lab and Mito-EpiGen Program’s Post

Rare Disease breakthroughs are important to everyone! Why’s that? The advances in treatment, or progression management, of rare diseases can provide trailblazing insights for more common ailments. This Virtual Public Meeting also an opportunity for organizations seeking to impact UN SDG3 - Health and Well-Being - because the United Nations Sustainable Development Goals and the 2030 Agenda seem to ensure that “no one is left behind.” No one being left behind requires that we address ALL diseases, no matter how small the patient population might be. The Chiaramello Lab and Mito-EpiGen Program Team will be joining this virtual meeting on Rare Diseases organized by FDA to conclude the Rare Disease Day. We encourage anyone interested in rare diseases, or more mainstream well-being issues, to join this opportunity to share ideas and learn from others. Our founder, Dr. Anne Chiaramello explains, “This is an invaluable opportunity for patients and providers to participate in discussions on clinical trials for rare diseases and on patient engagement at the FDA.” There will be a diverse range of speakers who will discuss topics including clinical research, FDA’s initiatives to advance rare disease medical product development and FDA’s patient engagement efforts. Free continuing education (CE) credit (4.25 hours) is available for eligible health care professionals, as well! In weeks following the Virtual Public Meeting, we will provide ideas about how any business can contribute to tackling rare diseases, to ensure that “no one is left behind.” #mitochondrialdisease #mitochondria #lhonplus #melas #rarediseaseday #rarediseaseday2024 #sdg3 #sdgs #2030agenda #clinicaltrials #innovationinhealth https://lnkd.in/gJcPtQMz